LeMaitre initiated with Neutral on valuation at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of LeMaitre with a Neutral rating and $96 price target LeMaitre is a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, the analyst tells investors in a research note. The firm holds a favorable view of the estimated $5B peripheral vascular device market and believes the company’s leading positions in niche markets should enable “steady” price increases. However, it initiates with a Neutral rating based on valuation, which Cantor believes fully reflects LeMaitre’s value.